tiprankstipranks
Advertisement
Advertisement

TSE:HLS Stock Latest News

HLS Therapeutics to Highlight CNS and Cardiovascular Portfolio at Bloom Burton Investor Conference
Company AnnouncementsHLS Therapeutics to Highlight CNS and Cardiovascular Portfolio at Bloom Burton Investor Conference
20d ago
HLS Therapeutics: Near-Term Softness Masking NILEMDO-Driven Growth Upside, Supporting Buy Rating
PremiumRatings
HLS Therapeutics: Near-Term Softness Masking NILEMDO-Driven Growth Upside, Supporting Buy Rating
2M ago
HLS Therapeutics price target lowered to C$4.45 from C$4.75 at Stifel
PremiumThe Fly
HLS Therapeutics price target lowered to C$4.45 from C$4.75 at Stifel
2M ago
HLS Therapeutics Lifts Profitability, Cuts Debt as It Expands Cardiovascular Portfolio
PremiumCompany Announcements
HLS Therapeutics Lifts Profitability, Cuts Debt as It Expands Cardiovascular Portfolio
2M ago
Is HLS a Buy, Before Earnings?
PremiumPre-Earnings
Is HLS a Buy, Before Earnings?
2M ago
HLS Therapeutics launches NILEMDO in Canada to tackle unmet cholesterol treatment needs
PremiumCompany AnnouncementsHLS Therapeutics launches NILEMDO in Canada to tackle unmet cholesterol treatment needs
2M ago
HLS Therapeutics launches NILEMDO in Canada to target unmet LDL-cholesterol needs
Premium
Company Announcements
HLS Therapeutics launches NILEMDO in Canada to target unmet LDL-cholesterol needs
2M ago
HLS Therapeutics Sets March 12 Date for Fiscal 2025 Results and Investor Call
Premium
Company Announcements
HLS Therapeutics Sets March 12 Date for Fiscal 2025 Results and Investor Call
2M ago
HLS Therapeutics price target raised to C$4.75 from C$4 at Stifel
PremiumThe Fly
HLS Therapeutics price target raised to C$4.75 from C$4 at Stifel
5M ago
Positive Outlook for HLS Therapeutics Inc. Amid Regulatory Developments and Product Approvals
PremiumRatings
Positive Outlook for HLS Therapeutics Inc. Amid Regulatory Developments and Product Approvals
5M ago
HLS Therapeutics Gains Health Canada Approval for NILEMDO®
PremiumCompany Announcements
HLS Therapeutics Gains Health Canada Approval for NILEMDO®
6M ago
HLS Therapeutics Inc.: Strategic Resilience and Growth Potential Amidst Market Challenges
PremiumRatings
HLS Therapeutics Inc.: Strategic Resilience and Growth Potential Amidst Market Challenges
6M ago
HLS Therapeutics Reports Mixed Earnings Amid Growth Challenges
PremiumCompany AnnouncementsHLS Therapeutics Reports Mixed Earnings Amid Growth Challenges
6M ago
HLS Therapeutics Reports Strong Q3 2025 Results and Prepares for New Product Launch
Premium
Company Announcements
HLS Therapeutics Reports Strong Q3 2025 Results and Prepares for New Product Launch
6M ago
HLS Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
HLS Upcoming Earnings Report: What to Expect?
6M ago
HLS Therapeutics to Announce Q3 2025 Financial Results
PremiumCompany Announcements
HLS Therapeutics to Announce Q3 2025 Financial Results
6M ago
HLS Therapeutics and Amarin Highlight Cardiovascular Advances at Canadian Congress
PremiumCompany Announcements
HLS Therapeutics and Amarin Highlight Cardiovascular Advances at Canadian Congress
7M ago
HLS Therapeutics Secures New Credit Agreement for Financial Flexibility
PremiumCompany Announcements
HLS Therapeutics Secures New Credit Agreement for Financial Flexibility
9M ago
HLS Therapeutics Inc: Strong Q2 Performance and Optimistic Outlook Justify Buy Rating
PremiumRatings
HLS Therapeutics Inc: Strong Q2 Performance and Optimistic Outlook Justify Buy Rating
9M ago
HLS Therapeutics Reports Strong Q2 2025 Financials and Strategic Expansion
PremiumCompany AnnouncementsHLS Therapeutics Reports Strong Q2 2025 Financials and Strategic Expansion
9M ago
HLS Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
HLS Earnings this Week: How Will it Perform?
9M ago
HLS Therapeutics to Announce Q2 2025 Financial Results
Premium
Company Announcements
HLS Therapeutics to Announce Q2 2025 Financial Results
9M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >